Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS)

Simple Summary The treatment of retroperitoneal sarcomas poses significant challenges due to their infrequency, clinical and histologic heterogeneity, and unique anatomical location. We provide an updated review on the management of retroperitoneal sarcoma and issue clear and concise recommendations for the treatment of the main clinical situations encountered in this disease. Abstract Soft tissue sarcomas (STS) are an uncommon and biologically heterogeneous group of tumors arising from mesenchymal cells. The incidence is estimated at five cases per 100,000 people per year. Retroperitoneal sarcomas (RPS) account for 10–15% of all STS, and their management depends on their anatomical characteristics and histotype. Due to their very low incidence, it is recommended that RPS be treated in reference centers and evaluated by an experienced multidisciplinary team (MDT). In Spain, the Spanish Group for Research in Sarcomas (GEIS) brings together experts from various specialties to promote research on sarcomas and improve treatment results. This paper summarizes the GEIS recommendations for the diagnosis, treatment, and follow-up of patients with RPS.

[1]  C. Serrano,et al.  Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database , 2023, Frontiers in Oncology.

[2]  J. M. Asencio,et al.  Surgical Principles of Primary Retroperitoneal Sarcoma in the Era of Personalized Treatment: A Review of the Frontline Extended Surgery , 2022, Cancers.

[3]  S. Litière,et al.  Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma , 2022, Annals of surgery.

[4]  D. Fan,et al.  Development and Validation of a Prognostic Model to Predict the Prognosis of Patients With Retroperitoneal Liposarcoma: A Large International Population-Based Cohort Study , 2022, Frontiers in Oncology.

[5]  Wei-qi Lu,et al.  Prognostic Factor Analysis and Nomogram Construction of Primary Retroperitoneal Liposarcoma: A Review of 10 Years of Treatment Experience in a Single Asian Cohort of 211 Cases , 2022, Frontiers in Oncology.

[6]  J. Trent,et al.  EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  C. Ong,et al.  Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal sarcomatosis-A systematic review and meta-analysis. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  S. Bonvalot,et al.  Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. , 2021, European journal of cancer.

[9]  F. Bertucci,et al.  LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study , 2021, Annals of Oncology.

[10]  J. Blay,et al.  Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. , 2021, European journal of cancer.

[11]  P. Delrio,et al.  Multidisciplinary Management of Retroperitoneal Sarcoma: Diagnosis, Prognostic Factors and Treatment , 2021, Cancers.

[12]  A. B. Hassan,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  J. Blay,et al.  Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma. , 2021 .

[14]  C. Raut,et al.  Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program , 2021, Current opinion in oncology.

[15]  John E. Mullinax,et al.  Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group , 2021, Annals of Surgical Oncology.

[16]  D. Fraker,et al.  Preoperative Biopsy in Patients with Retroperitoneal Sarcoma: Usage and Outcomes in a National Cohort , 2021, Annals of Surgical Oncology.

[17]  J. Martín-Broto,et al.  SEOM Clinical Guideline of management of soft-tissue sarcoma (2020) , 2021, Clinical and Translational Oncology.

[18]  Xiangji Li,et al.  Adjuvant therapy for retroperitoneal sarcoma: a meta-analysis , 2020, Radiation oncology.

[19]  C. Raut,et al.  Defining the role of neoadjuvant systemic therapy in high‐risk retroperitoneal sarcoma: A multi‐institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group , 2020, Cancer.

[20]  Patrick B. Schwartz,et al.  Renal Function After Retroperitoneal Sarcoma Resection with Nephrectomy: A Matched Analysis of the United States Sarcoma Collaborative Database , 2020, Annals of Surgical Oncology.

[21]  Anurag K. Singh,et al.  Evaluation of Preoperative Chemotherapy or Radiation and Overall Survival in Patients With Nonmetastatic, Resectable Retroperitoneal Sarcoma , 2020, JAMA network open.

[22]  K. Al-Dasuqi,et al.  Radiologic-Pathologic Correlation of Primary Retroperitoneal Neoplasms. , 2020, Radiographics : a review publication of the Radiological Society of North America, Inc.

[23]  J. Blay,et al.  Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. , 2020, The Lancet. Oncology.

[24]  J. Ro,et al.  Retroperitoneal Sarcomas: An Update on the Diagnostic Pathology Approach , 2020, Diagnostics.

[25]  J. Blay,et al.  Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG , 2020, Cancer.

[26]  A. Gronchi,et al.  Inoperable Primary Retroperitoneal Sarcomas: Clinical Characteristics and Reasons Against Resection at a Single Referral Institution , 2020, Annals of Surgical Oncology.

[27]  P. Rutkowski,et al.  Definitive Radiotherapy in the Management of Non-Resectable or Residual Retroperitoneal Sarcomas: Institutional Cohort Analysis and Systematic Review , 2020, Cancer control : journal of the Moffitt Cancer Center.

[28]  J. Blay,et al.  Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Hodson,et al.  Improved Biopsy Accuracy in Retroperitoneal Dedifferentiated Liposarcoma , 2020, Annals of Surgical Oncology.

[30]  A. Gronchi,et al.  Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine , 2020, CA: a cancer journal for clinicians.

[31]  J. Blay,et al.  Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group , 2020, Cancer.

[32]  J. Blay,et al.  Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. , 2020, JAMA oncology.

[33]  L. Mariani,et al.  Malnutrition and Perioperative Nutritional Support in Retroperitoneal Sarcoma Patients: Results from a Prospective Study , 2019, Annals of Surgical Oncology.

[34]  W. Al-Refaie,et al.  Identifying the Minimum Volume Threshold for Retroperitoneal Soft Tissue Sarcoma Resection: Merging National Data with Consensus Expert Opinion. , 2019, Journal of the American College of Surgeons.

[35]  B. Dickson,et al.  Early and Late Complications of Percutaneous Core Needle Biopsy of Retroperitoneal Tumors at Two Tertiary Sarcoma Centers , 2019, Annals of Surgical Oncology.

[36]  J. Blay,et al.  Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database , 2019, Annals of Surgical Oncology.

[37]  P. Rutkowski,et al.  OC-0069 5x5 Gy with chemotherapy in borderline resectable soft tissue sarcomas: early results of a trial , 2019, Radiotherapy and Oncology.

[38]  J. Hodson,et al.  Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma , 2019, British Journal of Surgery.

[39]  J. Blay,et al.  Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG , 2019, Clinical Cancer Research.

[40]  S. Bonvalot,et al.  Role of nutritional status in the early postoperative prognosis of patients operated for retroperitoneal liposarcoma (RLS): A single center experience. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[41]  Masanori Kawano,et al.  A meta-analysis of randomized controlled trials that compare standard doxorubicin with other first-line chemotherapies for advanced/metastatic soft tissue sarcomas , 2019, PloS one.

[42]  P. Casali,et al.  Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients—A propensity score analysis , 2018, Journal of surgical oncology.

[43]  M. Zucchetti,et al.  Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. , 2018, The Lancet. Oncology.

[44]  R. van Hillegersberg,et al.  Liver Resection for Hepatic Metastases from Soft Tissue Sarcoma: A Nationwide Study , 2018, Digestive Surgery.

[45]  Robin L. Jones,et al.  Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  Peter Wust,et al.  Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial , 2018, JAMA oncology.

[47]  K. Hunt,et al.  Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit , 2018, Annals of Surgical Oncology.

[48]  F. Bertucci,et al.  Improved survival using specialized multidisciplinary board in sarcoma patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  R. Abouassaly,et al.  Predictors of surgical quality for retroperitoneal sarcoma: Volume matters , 2017, Journal of surgical oncology.

[50]  F. Petrella,et al.  Pulmonary metastasectomy: an overview. , 2017, Journal of thoracic disease.

[51]  D. Jamieson,et al.  Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial , 2017 .

[52]  A. Lazar,et al.  Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard , 2017, Scientific Reports.

[53]  F. van Coevorden,et al.  Needle tract seeding following core biopsies in retroperitoneal sarcoma. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[54]  S. Bonvalot,et al.  Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[55]  S. Bonvalot,et al.  Post‐relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans‐Atlantic RPS Working Group , 2017, Cancer.

[56]  C. Shah,et al.  American Brachytherapy Society consensus statement for soft tissue sarcoma brachytherapy. , 2017, Brachytherapy.

[57]  S. Bonvalot,et al.  Essential Requirements for Quality Cancer Care : Soft Tissue arcoma in Adults and Bone Sarcoma . A critical review , 2017 .

[58]  N. Yamamoto,et al.  Sequential histological findings and clinical response after carbon ion radiotherapy for unresectable sarcoma , 2017, Clinical and translational radiation oncology.

[59]  R. Krempien,et al.  Intraoperative radiation therapy (IORT) in soft-tissue sarcoma , 2017, Radiation oncology.

[60]  B. Yeap,et al.  Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas , 2017, Advances in radiation oncology.

[61]  Robin L. Jones,et al.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  R. Gonzalez,et al.  Practical Issues for Retroperitoneal Sarcoma. , 2016, Cancer control : journal of the Moffitt Cancer Center.

[63]  D. Kirsch,et al.  Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. , 2016, The Lancet. Oncology.

[64]  S. Bonvalot,et al.  Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group , 2016, Annals of surgery.

[65]  F. Johnston,et al.  Neoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review , 2016, Journal of surgical oncology.

[66]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[67]  A. Crago,et al.  The importance of surgical margins in retroperitoneal sarcoma , 2016, Journal of surgical oncology.

[68]  Narasimhan P. Agaram,et al.  Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma , 2016, Annals of surgery.

[69]  L. Constine,et al.  The Benefit of Adjuvant Radiotherapy in High-grade Nonmetastatic Retroperitoneal Soft Tissue Sarcoma: A SEER Analysis , 2015, American journal of clinical oncology.

[70]  K. Fritchie.  Diagnostically Challenging "Fatty" Retroperitoneal Tumors. , 2015, Surgical pathology clinics.

[71]  R. Abrams,et al.  Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel. , 2015, International journal of radiation oncology, biology, physics.

[72]  Seung-Yong Jeong,et al.  Prognostic factors for reoperation of recurrent retroperitoneal sarcoma: The role of clinicopathological factors other than histologic grade , 2015, Journal of surgical oncology.

[73]  A. D. Dei Tos,et al.  High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma , 2014, Clinical Sarcoma Research.

[74]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[75]  J. Blay,et al.  Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  L. Qin,et al.  Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Luigi Mariani,et al.  Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Jean-Yves Blay,et al.  Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. , 2012, The Lancet. Oncology.

[79]  J. Blay,et al.  Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). , 2012, The oncologist.

[80]  T. Nielsen,et al.  Pazopanib for metastatic soft-tissue sarcoma , 2012, The Lancet.

[81]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[82]  A. Ravaud,et al.  Lung Tumors Treated With Percutaneous Radiofrequency Ablation: Computed Tomography Imaging Follow-Up , 2011, CardioVascular and Interventional Radiology.

[83]  John E. Mullinax,et al.  Current diagnosis and management of retroperitoneal sarcoma. , 2011, Cancer control : journal of the Moffitt Cancer Center.

[84]  J. Maurel,et al.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  L. Qin,et al.  Predicting Outcome by Growth Rate of Locally Recurrent Retroperitoneal Liposarcoma: The One Centimeter Per Month Rule , 2009, Annals of surgery.

[86]  R. Pollock,et al.  The role of surgical margin status in retroperitoneal sarcoma , 2008, Journal of surgical oncology.

[87]  Tohru Okada,et al.  Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. , 2007, International journal of radiation oncology, biology, physics.

[88]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  T. Delaney,et al.  Results of radiation therapy for unresected soft-tissue sarcomas. , 2005, International journal of radiation oncology, biology, physics.

[90]  J. Ioannidis,et al.  18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[91]  Samuel Singer,et al.  Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma , 2003, Annals of surgery.

[92]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[93]  P. Terrier,et al.  Prognostic factors in retroperitoneal sarcoma , 2001, Cancer.

[94]  J. Tepper,et al.  Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. , 1993, Archives of surgery.

[95]  M. Ranney,et al.  Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.

[96]  José Manuel Asencio Pascual,et al.  Update in pelvic and retroperitoneal sarcoma management: The role of compartment surgery. , 2019, Cirugia espanola.

[97]  R. Miceli,et al.  Prognostic models for RPS patients—Attempting to predict patient outcomes , 2018, Journal of surgical oncology.

[98]  R. Canter,et al.  Post‐operative surveillance in retroperitoneal soft tissue sarcoma: The importance of tumor histology in guiding strategy , 2018, Journal of surgical oncology.

[99]  B. Dickson,et al.  Results of Resection for Recurrent or Residual Retroperitoneal Sarcoma After Failed Primary Treatment , 2016, Annals of Surgical Oncology.

[100]  F. Collin,et al.  Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. , 2016, European journal of cancer.

[101]  T. Group,et al.  Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group , 2016, Annals of Surgical Oncology.

[102]  Merina Ahmed,et al.  Stereotactic body radiotherapy for oligometastases. , 2013, The Lancet. Oncology.

[103]  S. Sleijfer,et al.  Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom , 2010, European journal of cancer.

[104]  W. Knoefel,et al.  Benefit of surgical treatment of lung metastasis in soft tissue sarcoma. , 2007, Archives of surgery.